ConductScience.org, home

Gene · 58498

MYL7: myosin light chain 7

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. MYL7: myosin light chain 7. Genes, record 58498. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/58498

On this page

Gene

Symbol
MYL7
HGNC
Name
myosin light chain 7
HGNC
NCBI Gene ID
58498
NCBI Gene
HGNC ID
HGNC:21719
HGNC
Ensembl
ENSG00000106631
NCBI Gene
Aliases
MYL2A, MYLC2A
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q01449Myosin regulatory light chain 2, atrial isoform1750Ensembl, GeneID, HGNC

Source UniProt

Patents22

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1454749Q01449Espacenet
JP 2024128028 A2024-09-2027Q01449Espacenet
US 11760977 B22023-09-1927Q01449Espacenet
JP 2023123507 A2023-09-05305Q01449Espacenet
US 11685901 B22023-06-2727Q01449Espacenet
JP 2022153580 A2022-10-1227Q01449Espacenet
US 11446398 B22022-09-2054600Q01449Espacenet
JP 2022524081 A2022-04-27157571Q01449Espacenet
JP 2022504640 A2022-01-1397Q01449Espacenet
EP 3863659 A12021-08-1827Q01449Espacenet

1 to 10 of 22

See all 22 patents

Drugs3

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
DANICAMTIVCHEMBL4594304Cardiac myosin activatorACTIVATORChEMBL
MAVACAMTENCHEMBL4297517Cardiac myosin inhibitorINHIBITORChEMBL
OMECAMTIV MECARBILCHEMBL1800955Cardiac myosin activatorACTIVATORChEMBL

Trials45

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

NIH grants855

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleMYL7 papersNewest fiscal year
R01HL076485Engineering Vascularized Cardiac Muscle72025
R01HL113006Human Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling72025
R01HL128368Engineered Stem Cells for Cardiac Repair42025
R01HL151505Oxylipin Signaling in Congenital Heart Disease42025
P30CA014520UW Comprehensive Cancer Center Support32025
P30DK017047Diabetes Research Center32025
R01HL085844Functional interactions of cardiac ion channels32025
R01HL130020Elucidating Mechanism of Cardiac Fibrosis with Cell Village of Pooled Human iPSCs32025
R01HL131017Myocardial remuscularization by cardiac patch delivery of epicardial FSTL1 and CCND2 overexpressing cardiomyocytes32025
R01HL133230Mechanisms for cell signaling in the control of cardiomyogenesis32025

1 to 10 of 855Source NIH's project files

See all 855 nih grants

Papers788

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
PIP3 antagonist as a molecular regulator in MSC-derived cardiomyocytes: Potential in vitro therapeutic implications for conotruncal heart defects.J Genet Eng Biotechnol202642749427PubTator, text miningPubMed
Human plasma-like medium enhances structural and metabolic maturation of human pluripotent stem cell-derived cardiomyocytes.Bioeng Transl Med202642272985PubTator, text miningPubMed
Coaxially Electrospun Myocardial dECM- Based Nanofibrous Scaffolds Demonstrate Enhanced Cardiomyocyte Biocompatibility.Adv Healthc Mater202642152235PubTator, text miningPubMed
Characterisation of a Missense Variant of the Alström Syndrome Centrosome and Basal Body Associated Protein (ALMS1) Gene Associated with Cardiomyopathy Using Induced Pluripotent Stem Cells.Genes (Basel)202641751610PubTator, text miningPubMed
Pro- and Anti-Inflammatory Cytokines' Implication in Right Heart Disease, Arrhythmogenesis, and Atrial Fibrillation.Biomolecules202641750286PubTator, text miningPubMed
Single-Cell Multi-Omics Profiling of Human Septal Myectomy Tissue: Toward Precision Medicine in Obstructive Hypertrophic Cardiomyopathy.J Pers Med202641745380PubTator, text miningPubMed
Biomimetic electrospun scaffolds for engineered heart tissue: from design parameters to drug testing platforms.Front Bioeng Biotechnol202641743838PubTator, text miningPubMed
TCA cycle intermediates as an adjunct strategy for human iPSC-derived cardiomyocyte maturation.BBA Adv202641743073PubTator, text miningPubMed
Deep immune-phenotyping of HLA-homozygous iPS-cardiomyocytes by spectral flow cytometry.Front Immunol202641716415PubTator, text miningPubMed
PreTSA: computationally efficient modeling of temporal and spatial gene expression patterns.Genome Biol202641673899PubTator, text miningPubMed

1 to 10 of 788

See all 788 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/58498

GET https://conductscience.org/api/genes/v1/58498/patents?page=2